InViragen and Duke-NUS Form Collaborative Vaccine Research and Development Program
Published: Jan 27, 2011
FORT COLLINS, Colo. & SINGAPORE--(BUSINESS WIRE)--Inviragen, Inc. and the Duke-National University of Singapore Graduate Medical School (“Duke-NUS”) announced today that they have completed a memorandum of understanding (MOU) to establish a partnership between the two organizations. The goal of the partnership is to better understand how emerging infectious diseases are transmitted and how transmission can be prevented. Through this collaborative program, Inviragen and Duke-NUS aim to advance the research and development of vaccines against infectious diseases such as dengue fever, hand, foot and mouth disease and chikungunya.